a Center of Excellence for Aging and Brain Repair, Department of Neurosurgery and Brain Repair , University of South Florida Morsani College of Medicine , Tampa , FL , USA.
b Centro de Investigación en Ciencias de la Salud (CICSA), Facultad de Ciencias de la Salud , Universidad Anáhuac México Campus Norte , Huixquilucan, Edo. de Mexico , México.
Expert Opin Biol Ther. 2019 Jan;19(1):25-33. doi: 10.1080/14712598.2019.1551872. Epub 2018 Dec 13.
Stroke is a major cause of mortality and disability with a narrow therapeutic window. Stem cell therapy may enhance the stroke recovery.
Regenerative medicine via stem cells stands as a novel therapy for stroke. In particular, bone marrow-derived mesenchymal stem cells (MSCs) have neuroprotective and anti-inflammatory properties that improve brain function after stroke. Here, we discuss the safety, efficacy, and mechanism of action underlying the therapeutic effects of bone marrow-derived MSCs. We also examine the discrepant transplant protocols between preclinical studies and clinical trials. Laboratory studies show the safety and efficacy of bone marrow-derived MSCs in stroke models. However, while safe, MSCs remain to be fully evaluated as effective in clinical trials. Furthermore, recognizing the multiple cell death processes associated with stroke, we next discuss the potential therapeutic benefits of a combination therapy. With preliminary results and on-going clinical trials, a careful assessment of dosing, timing, and delivery route regimens will further direct the future of stem cell therapy for neurological disorders, including stroke.
Bone marrow-derived MSCs appear to be the optimal stem cell source for stroke therapy. Optimizing dosing, timing, and delivery route should guide the clinical application of bone marrow-derived MSCs.
中风是一种具有较窄治疗窗口的主要致死和致残原因。干细胞疗法可能会增强中风的恢复效果。
通过干细胞的再生医学为中风提供了一种新的治疗方法。具体来说，骨髓间充质干细胞（MSCs）具有神经保护和抗炎特性，可改善中风后的大脑功能。在这里，我们讨论了骨髓来源的 MSCs 治疗效果的安全性、有效性和作用机制。我们还研究了临床前研究和临床试验之间移植方案的差异。实验室研究表明，骨髓来源的 MSCs 在中风模型中是安全且有效的。然而，尽管安全，MSCs 仍需在临床试验中充分评估其有效性。此外，鉴于中风与多种细胞死亡过程有关，我们接下来讨论了联合治疗的潜在治疗益处。随着初步结果和正在进行的临床试验，仔细评估剂量、时间和输送途径方案将进一步指导包括中风在内的神经疾病的干细胞治疗的未来。
骨髓来源的 MSCs 似乎是中风治疗的最佳干细胞来源。优化剂量、时间和输送途径应指导骨髓来源的 MSCs 的临床应用。
